drugset / Trial / NCT02933099
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
Phase 3
Unknown
300 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RandomizedParallel-groupOpen-labelSupportive care
Summary
To compare the antiemetic combination of palonosetron, dexamethasone, and aprepitant (PDA) with antiemetic combination of palonosetron and dexamethasone (PD) in nasopharyngeal carcinoma patients receiving docetaxel, cisplatin, and 5-FU based chemotherapy.
Timeline
- Start
- 2016-10
- Primary completion
- 2018-04
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 8 mg | Oral |
| Comparator | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |